12:00 AM
Aug 06, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Afinitor regulatory update

The European Commission approved Afinitor everolimus from Novartis in combination with Aromasin exemestane to treat postmenopausal women with hormone receptor-positive, HER2-negative breast cancer that has progressed after treatment with a non-steroidal aromatase inhibitor. Last month, FDA approved the oral ...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >